172 related articles for article (PubMed ID: 23880663)
1. Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis.
Cheng W; Curti E; Rezende WC; Kwityn C; Zhan B; Gillespie P; Plieskatt J; Joshi SB; Volkin DB; Hotez PJ; Middaugh CR; Bottazzi ME
Hum Vaccin Immunother; 2013 Nov; 9(11):2351-61. PubMed ID: 23880663
[TBL] [Abstract][Full Text] [Related]
2. Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis.
Curti E; Kwityn C; Zhan B; Gillespie P; Brelsford J; Deumic V; Plieskatt J; Rezende WC; Tsao E; Kalampanayil B; Hotez PJ; Bottazzi ME
Hum Vaccin Immunother; 2013 Nov; 9(11):2342-50. PubMed ID: 23899507
[TBL] [Abstract][Full Text] [Related]
3. Solution structure, membrane interactions, and protein binding partners of the tetraspanin Sm-TSP-2, a vaccine antigen from the human blood fluke Schistosoma mansoni.
Jia X; Schulte L; Loukas A; Pickering D; Pearson M; Mobli M; Jones A; Rosengren KJ; Daly NL; Gobert GN; Jones MK; Craik DJ; Mulvenna J
J Biol Chem; 2014 Mar; 289(10):7151-7163. PubMed ID: 24429291
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of Schistosoma mansoni tegument annexins and comparative analysis of antibody responses following parasite infection.
Leow CY; Willis C; Leow CH; Hofmann A; Jones M
Mol Biochem Parasitol; 2019 Dec; 234():111231. PubMed ID: 31628972
[TBL] [Abstract][Full Text] [Related]
5.
Morais SB; Figueiredo BC; Assis NRG; Homan J; Mambelli FS; Bicalho RM; Souza C; Martins VP; Pinheiro CS; Oliveira SC
Front Immunol; 2018; 9():1762. PubMed ID: 30105029
[TBL] [Abstract][Full Text] [Related]
6. Protection and immunological study on two tetraspanin-derived vaccine candidates against schistosomiasis japonicum.
Chen L; Chen Y; Zhang D; Hou M; Yang B; Zhang F; Zhang W; Luo X; Ji M; Wu G
Parasite Immunol; 2016 Oct; 38(10):589-98. PubMed ID: 27189226
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the use of C-terminal part of the Schistosoma mansoni 200kDa tegumental protein in schistosomiasis diagnosis and vaccine formulation.
Carvalho GB; Pacífico LG; Pimenta DL; Siqueira LM; Teixeira-Carvalho A; Coelho PM; Pinheiro Cda S; Fujiwara RT; Oliveira SC; Fonseca CT
Exp Parasitol; 2014 Apr; 139():24-32. PubMed ID: 24560833
[TBL] [Abstract][Full Text] [Related]
8. Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2.
Pearson MS; Pickering DA; McSorley HJ; Bethony JM; Tribolet L; Dougall AM; Hotez PJ; Loukas A
PLoS Negl Trop Dis; 2012; 6(3):e1564. PubMed ID: 22428079
[TBL] [Abstract][Full Text] [Related]
9. A multivalent chimeric vaccine composed of Schistosoma mansoni SmTSP-2 and Sm29 was able to induce protection against infection in mice.
Pinheiro CS; Ribeiro AP; Cardoso FC; Martins VP; Figueiredo BC; Assis NR; Morais SB; Caliari MV; Loukas A; Oliveira SC
Parasite Immunol; 2014 Jul; 36(7):303-12. PubMed ID: 24749785
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism associated with the Schistosoma mansoni tetraspanin-2 gene.
Cupit PM; Steinauer ML; Tonnessen BW; Eric Agola L; Kinuthia JM; Mwangi IN; Mutuku MW; Mkoji GM; Loker ES; Cunningham C
Int J Parasitol; 2011 Oct; 41(12):1249-52. PubMed ID: 21889508
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area.
Keitel WA; Potter GE; Diemert D; Bethony J; El Sahly HM; Kennedy JK; Patel SM; Plieskatt JL; Jones W; Deye G; Bottazzi ME; Hotez PJ; Atmar RL
Vaccine; 2019 Oct; 37(43):6500-6509. PubMed ID: 31515141
[TBL] [Abstract][Full Text] [Related]
12. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis.
Tran MH; Pearson MS; Bethony JM; Smyth DJ; Jones MK; Duke M; Don TA; McManus DP; Correa-Oliveira R; Loukas A
Nat Med; 2006 Jul; 12(7):835-40. PubMed ID: 16783371
[TBL] [Abstract][Full Text] [Related]
13. Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental Schistosoma mansoni infection.
Ewaisha RE; Bahey-El-Din M; Mossallam SF; Amer EI; Aboushleib HM; Khalil AM
Exp Parasitol; 2014 Oct; 145():51-60. PubMed ID: 25092439
[TBL] [Abstract][Full Text] [Related]
14. Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine.
Zhang W; Ahmad G; Torben W; Noor Z; Le L; Damian RT; Wolf RF; White GL; Chavez-Suarez M; Podesta RB; Kennedy RC; Siddiqui AA
J Infect Dis; 2010 Apr; 201(7):1105-12. PubMed ID: 20187746
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of thyroid hormone receptor beta from Schistosoma japonicum and assessment of its potential as a vaccine candidate antigen against schistosomiasis in BALB/c mice.
Qiu C; Liu S; Hong Y; Fu Z; Wei M; Ai D; Lin J
Parasit Vectors; 2012 Aug; 5():172. PubMed ID: 22889153
[TBL] [Abstract][Full Text] [Related]
16. Development of a conserved chimeric vaccine based on helper T-cell and CTL epitopes for induction of strong immune response against Schistosoma mansoni using immunoinformatics approaches.
Rahmani A; Baee M; Rostamtabar M; Karkhah A; Alizadeh S; Tourani M; Nouri HR
Int J Biol Macromol; 2019 Dec; 141():125-136. PubMed ID: 31479669
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of Schistosoma mansoni antigens recognized by T and B lymphocytes of humans with early active intestinal and/or urinary schistosomiasis.
al-Sherbiny M; el Ridi R; Guirguis NI; Dean DA
Int J Parasitol; 1995 Jan; 25(1):113-21. PubMed ID: 7541026
[TBL] [Abstract][Full Text] [Related]
18. Process development for production and purification of the Schistosoma mansoni Sm14 antigen.
Damasceno L; Ritter G; Batt CA
Protein Expr Purif; 2017 Jun; 134():72-81. PubMed ID: 28389350
[TBL] [Abstract][Full Text] [Related]
19. Inconsistent protective efficacy and marked polymorphism limits the value of Schistosoma japonicum tetraspanin-2 as a vaccine target.
Zhang W; Li J; Duke M; Jones MK; Kuang L; Zhang J; Blair D; Li Y; McManus DP
PLoS Negl Trop Dis; 2011; 5(5):e1166. PubMed ID: 21655308
[TBL] [Abstract][Full Text] [Related]
20. DNA Vaccine Encoding the Chimeric Form of Schistosoma mansoni Sm-TSP2 and Sm29 Confers Partial Protection against Challenge Infection.
Gonçalves de Assis NR; Batistoni de Morais S; Figueiredo BC; Ricci ND; de Almeida LA; da Silva Pinheiro C; Martins Vde P; Oliveira SC
PLoS One; 2015; 10(5):e0125075. PubMed ID: 25942636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
